Vaxdyn is dedicated to prevent and alleviate the effects of the global health crisis caused by superbacteria, the pathogenic bacteria developing resistance to available antibiotics.
Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators on development of multi-valent vaccines for preventing antibiotic-resistant infections in all regions of the world.
Vaxdyn’s vaccines target high-risk populations. Population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates.
Vaxdyn was founded as a spin-off established by researchers of the Institute of Biomedicine of Seville, a center of the Andalusian Public Health System and the University of Seville linked to the University Hospital Virgen del Rocío of Seville. Decades of research on antibiotic-resistant bacteria led to AcinetoVax, a very unique vaccine candidate against multi-drug resistant Acinetobacter baumannii protected by an international patent family published as WO 2015/169809 and granted in many jurisdictions.